What is CERT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.44B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CERT?

P/E (TTM) is n/a and 52-week range is $4.45 to $12.94 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CERT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CERT?

The company profile lists revenue (TTM) near $412M, net income (TTM) near -$6.89B, EPS (TTM) near -$0.44 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Certara Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Radnor, Pennsylvania, US, 155.6M shares outstanding, ISIN US15687V1098 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Certara Inc

$CERT

Health Care · Health Care Technology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. The company is headquartered in Radnor, Pennsylvania and currently employs 1,515 full-time employees. The company went IPO on 2020-12-11. The company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. The company delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. The company offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

Employees

1,515

Website

www.certara.com/

IPO

2020-12-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)